| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | PPARGC1B |
| Uniprot No | Q86YN6 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 868-1023aa |
| 氨基酸序列 | TRRNFRCESRGPCSDRTPSIRHARKRREKAIGEGRVVYIQNLSSDMSSRELKRRFEVFGEIEECEVLTRNRRGEKYGFITYRCSEHAALSLTKGAALRKRNEPSFQLSYGGLRHFCWPRYTDYDSNSEEALPASGKSKYEAMDFDSLLKEAQQSLH |
| 预测分子量 | 25.6 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于PPARGC1B重组蛋白的模拟参考文献示例(仅供格式参考，实际文献需通过学术数据库查询)：
---
1. **文献名称**: *Recombinant PPARGC1B Protein Enhances Mitochondrial Biogenesis in Skeletal Muscle Cells*
**作者**: Zhang et al. (2018)
**摘要**: 本研究通过大肠杆菌表达系统成功纯化出重组PPARGC1B蛋白，并证实其可激活骨骼肌细胞中线粒体生物合成相关基因，改善细胞能量代谢效率。实验表明，外源性PPARGC1B可提升ATP产量并增强胰岛素敏感性。
2. **文献名称**: *PPARGC1B Co-Activates PPARγ in Lipid Metabolism: Evidence from In Vitro Reconstitution Assays*
**作者**: Smith & Lee (2020)
**摘要**: 利用重组PPARGC1B和PPARγ蛋白进行体外共激活实验，发现PPARGC1B显著增强PPARγ对脂质分解基因的调控作用，提示两者在脂肪代谢中的协同机制可能成为代谢综合征的治疗靶点。
3. **文献名称**: *Functional Characterization of PPARGC1B Polymorphisms Using Recombinant Protein Variants*
**作者**: Kumar et al. (2019)
**摘要**: 通过构建携带不同单核苷酸多态性(SNP)的重组PPARGC1B蛋白，发现rs7732671突变体导致其与转录因子ERRα的结合能力下降，可能与肥胖患者的代谢功能障碍相关。
---
**注意**：以上为模拟生成的示例，实际研究中请通过PubMed、Web of Science等平台检索真实文献。建议使用关键词“PPARGC1B recombinant protein”或“PPARGC1B functional study”进行精准查询。
PPARGC1B (peroxisome proliferator-activated receptor gamma coactivator 1-beta), also known as PERC, is a transcriptional coactivator involved in regulating energy metabolism, mitochondrial biogenesis, and adaptive thermogenesis. It belongs to the PGC-1 family, sharing structural and functional similarities with PPARGC1A (PGC-1α). Primarily expressed in metabolically active tissues like skeletal muscle, heart, and liver, PPARGC1B interacts with nuclear receptors (PPARs, ERRs) and transcription factors to modulate genes critical for oxidative phosphorylation, fatty acid oxidation, and glucose homeostasis.
Recombinant PPARGC1B protein is engineered in vitro using expression systems (e.g., E. coli, mammalian cells) to produce purified, functional protein for research. Its structure includes an N-terminal activation domain, a central regulatory region with phosphorylation sites, and a C-terminal RNA-binding domain. The recombinant form often retains LXXLL motifs essential for nuclear receptor binding, enabling studies on its role in metabolic pathways.
Research applications focus on metabolic diseases (e.g., obesity, diabetes), neurodegenerative disorders, and cancer, where PPARGC1B dysregulation is implicated. Recombinant proteins facilitate investigations into protein-protein interactions, post-translational modifications (phosphorylation, acetylation), and downstream signaling. Mutant variants are used to dissect functional domains or disease-associated polymorphisms (e.g., rs7732671 linked to obesity).
As a therapeutic target, recombinant PPARGC1B aids in drug screening to identify modulators of mitochondrial function or insulin sensitivity. Its role in exercise-induced metabolic adaptation and tissue-specific energy regulation underscores its biomedical relevance, driving interest in engineered forms for mechanistic and translational studies.
×
